Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consens

Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the ana

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or th

BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.

Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad

HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a

Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stag

CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or th

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors a

The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in th

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consens

CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a lik

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or t

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak

Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the busines

– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Ach

HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Apo

CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or th

New York State Common Retirement Fund raised its stake in Heron Therapeutics, Inc. (NASDAQ: HRTX) by

HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-sta

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-sta

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the ana

Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.10) per share which missed the ana

Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stag

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers t

Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.02) per share which missed the ana

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:H

Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.00 million-$163.00 million t

Heron Therapeutics (NASDAQ:HRTX) reported quarterly earnings of $0.01 per share which beat the analy

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintai